Cloning and mapping of a human RBP56 gene encoding a putative RNA binding protein similar to FUS/TLS and EWS proteins

Genomics
F MorohoshiM Ohki

Abstract

The EWS gene was found at the chromosome breakpoints in Ewing sarcoma, and the FUS/TLS gene was found at the breakpoints of myxoid liposarcoma and acute myeloid leukemia. These genes encode proteins that carry a highly homologous RNA binding domain. Fusion proteins made of the N-terminal half of EWS or FUS/TLS and transcriptional regulatory proteins, also derived from genes located at breakpoints, have been suggested to be involved in the pathogenesis of tumors. By PCR amplification of human Namalwa cell cDNA using degenerate primers made from the conserved amino acid sequences in the RNA binding domain of EWS and FUS/TLS, we obtained a cDNA fragment (RBP56 cDNA), the predicted amino acid sequences of which were similar but not identical to those of EWS and FUS/TLS. Using this fragment as a probe, we obtained two isoforms of cDNAs consisting of 2144 and 2153 bp, respectively, which encode proteins consisting of 589 and 592 amino acid residues, respectively. The predicted amino acid sequences of RBP56 protein have a serine-, tyrosine-, glutamine-, and glycine-rich region in the N-terminal region, an RNA binding domain and a C2C2 finger motif in the central region, and degenerate repeats of DR(S)GG(G)-YGG sequences in the C-termi...Continue Reading

Citations

Apr 15, 1999·The EMBO Journal·S NakielnyG Dreyfuss
Aug 12, 2010·Human Molecular Genetics·Daryl A BoscoLawrence J Hayward
Sep 29, 2009·Journal of Molecular Cell Biology·Adelene Y Tan, James L Manley
Jan 22, 2011·Sarcoma·Rachel ConyersDavid M Thomas
Oct 30, 2016·RNA Biology·Francesca SvetoniMaria Paola Paronetto
Nov 6, 2004·Cancer Genetics and Cytogenetics·Avery A Sandberg
Jun 10, 2004·Genes, Chromosomes & Cancer·Masanori HisaokaHiroshi Hashimoto
Jun 10, 2004·Current Opinion in Oncology·Avery A Sandberg
Aug 11, 2007·The Journal of Pathology·N RiggiI Stamenkovic
Sep 21, 2007·Proteomics·Giovanna Maria PierantoniAlfredo Fusco
Mar 12, 2008·International Journal of Cancer. Journal International Du Cancer·Sol KimJungho Kim
Nov 26, 2009·Virchows Archiv : an International Journal of Pathology·Salvatore Romeo, Angelo P Dei Tos
Apr 20, 2004·FEBS Letters·Hye Jin LeeJungho Kim
Jan 1, 2008·Bioinformatics and Biology Insights·Susan M Corley, Jill E Gready
Jan 30, 2014·Molecular Biology Reports·Marija MarkoApostolia Guialis
Mar 26, 2011·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·N TicozziJ E Landers
Oct 29, 2008·The Biochemical Journal·Mariola J EdelmannBenedikt M Kessler
Apr 10, 2019·EMBO Reports·Malin LindénPierre Åman
Mar 3, 2020·Frontiers in Molecular Biosciences·Joshua A ImperatoreMihaela Rita Mihailescu
Feb 13, 2001·Biochemical and Biophysical Research Communications·I PanagopoulosN Mandahl

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.